CODEMA PHARMA
Sources: the KBO register on 22-11-2026; the National Bank, 2025 annual accounts filed on 31-08-2026; the Belgian Official Gazette, latest deed of 17-03-2026.
Grounds
the facts the verdict rests on, each with its source- In 2025, CODEMA PHARMA made a loss of €32,963.Annual accounts 2025 page 2
- Equity stands at €71,289, or 19.0% of the balance sheet total of €375,959. The solvency of 19.0% is higher than at 38% of the 25,459 companies filing micro accounts in retail trade (NACE 47) in 2025.Annual accounts 2025 page 2
- The 2025 accounts reached the National Bank on 31-08-2026, 31 days after the term.National Bank, filing of 31-08-2026 page 4
Representation
Two directors jointly represent CODEMA PHARMA. The sole director is .
Articles of association, Belgian Official Gazette of 27-07-2017, deed 17317541
Ownership
The accounts in the micro format list no shareholders. holds 825 shares. There are 2 other shareholders.
Deed of 27-07-2017
Financial situation
Annual accounts 2021 to 2025, as filed with the National Bank
Gross margin and net resultin euro
Equity and debtsin euro
Cashin euro
| Financial year | 2021 | 2022 | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|---|
| Results | ||||||
| Gross margin | -€45,417 | -€38,441 | €399,803 | -€8,983 | -€34,489 | |
| Operating result | -€77,498 | -€54,805 | €399,803 | -€8,983 | -€34,489 | |
| Net result | -€77,693 | -€55,909 | €400,670 | -€9,231 | -€32,963 | |
| Balance sheet at the closing date | ||||||
| Equity | -€231,278 | -€287,186 | €113,483 | €104,252 | €71,289 | |
| Debts | €302,600 | €339,508 | €297,786 | €305,645 | €304,670 | |
| Debts due after more than one year | €10,000 | - | - | - | - | |
| Debts due within one year | €290,932 | €337,841 | €296,118 | €303,977 | €304,670 | |
| Cash | €3,610 | €1,635 | €1,580 | €1,639 | €2,366 | |
| Balance sheet total | €71,322 | €52,322 | €411,269 | €409,897 | €375,959 | |
| Ratios | ||||||
| Solvency | -324.3% | -548.9% | 27.6% | 25.4% | 19.0% | |
| Liquidity | 0.19 | 0.15 | 1.39 | 1.35 | 1.23 | |
Source: Annual accounts 2025, micro format, filed on 31-08-2026 (2026-00497957); Annual accounts 2024, micro format, filed on 14-07-2025 (2025-00272048); Annual accounts 2021 to 2023, filed from 26-07-2022 to 24-07-2024 (2022-20232836, 2023-00267667, 2024-00285604).
The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.
CODEMA PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from -€8,983 to -€34,489.
Board, signature and ownership
Position on 22-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
Two directors jointly represent CODEMA PHARMA. The sole director is .
Articles of association, Belgian Official Gazette of 27-07-2017, deed 17317541
Board
one director in officeOwnership and group
Shareholders
The accounts in the micro format list no shareholders. holds 825 shares. holds 825 shares. holds 14,850 shares.
Deed of 27-07-2017
Board changes
and resign. appointed. General meeting of 07-06-2023.
Gazette, deed 23079177resigns as director. appointed as director. General meeting of 06-04-2018.
Gazette, deed 18070666Events and comparison
The last 24 months, newest first
Annual accounts 2025 filed, 31 days late.
NBB filingRegistered office moved from Woluwe St Lambert to Brussels. The registered office moved from Clos Chapelle aux Champs 30, 1200 Woluwe St Lambert to Rond-Point Schuman 2-4 (Levels 5 & 6, EU Quarter) à 1040 Bruxelles.
Gazette, deed 26038269Address struck.
KBO administrationAnnual accounts 2024 filed, 17 days before the deadline.
NBB filingComparable companies, two years later
In July 2024, 1,546 companies had the same profile as CODEMA PHARMA has now: micro, 5 to 10 years old, solvency 10 to 30% and a small loss. Two years later 91.3% were still trading, 4.3% had stopped another way and 4.3% had gone bankrupt.
The return on assets of CODEMA PHARMA, -8.8%, is higher than at 19% of the 24,646 companies filing micro accounts in retail trade (NACE 47) in 2025.
Other findings
Peppol
Not listed in the Peppol Directory.
Sanctions lists
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 22-11-2026 | KBO 0678.830.942 |
| National Bank of Belgium | Annual accounts 2025, micro format | 31-08-2026 | 2026-00497957 |
| National Bank of Belgium | Annual accounts 2024, micro format | 14-07-2025 | 2025-00272048 |
| National Bank of Belgium | Annual accounts 2021 to 2023 | 26-07-2022 to 24-07-2024 | 2022-20232836, 2023-00267667, 2024-00285604 |
| Belgian Official Gazette | Board | 19-06-2023 | deed 23079177 |
| Belgian Official Gazette | Board | 02-05-2018 | deed 18070666 |
| Belgian Official Gazette | Articles of association with the signing rule | 27-07-2017 | deed 17317541 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 19-11-2026 | |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 21-11-2026 | bankruptcy model of 21 November 2026 |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 21 November 2026, computed on 21-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.
The scores and ratios are Checked's own calculations, not a credit decision.